{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:44:14Z","timestamp":1765208654211,"version":"3.46.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.7759\/cureus.98714","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:47:09Z","timestamp":1765205229000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case Report on a Challenge From Diagnosis to Treatment: Interstitial Lung Disease As the First Manifestation of Systemic Sclerosis Sine Scleroderma"],"prefix":"10.7759","author":[{"given":"Susana","family":"Viana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia","family":"S\u00e1 Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Guiomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"M\u00f4\u00e7o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2397198320903867","article-title":"Pathogenesis of systemic sclerosis associated interstitial lung disease","volume":"5","author":"Nihtyanova SI","year":"2020","unstructured":"Nihtyanova SI, Denton CP. Pathogenesis of systemic sclerosis associated interstitial lung disease. J Scleroderma Relat Disord. 2020, 5:6-16. 10.1177\/2397198320903867","journal-title":"J Scleroderma Relat Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.4.976","article-title":"Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease","volume":"130","author":"Fischer A","year":"2006","unstructured":"Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest. 2006, 130:976-81. 10.1378\/chest.130.4.976","journal-title":"Chest"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2022.01.023","article-title":"Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma","volume":"365","author":"Chong WH","year":"2023","unstructured":"Chong WH, Saha BK, Beegle S. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma. Am J Med Sci. 2023, 365:198-204. 10.1016\/j.amjms.2022.01.023","journal-title":"Am J Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin V","year":"2019","unstructured":"Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019, 20:13. 10.1186\/s12931-019-0980-7","journal-title":"Respir Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen F","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al.. 2013 classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013, 72:1747-55. 10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas A","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020, 8:304-13. 10.1016\/S2213-2600(19)30480-1","journal-title":"Lancet Respir Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna D","year":"2020","unstructured":"Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020, 201:650-60. 10.1164\/rccm.201903-0563CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo F","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, et al.. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025, 84:29-40. 10.1136\/ard-2024-226430","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi FF","year":"2023","unstructured":"Rahaghi FF, Hsu VM, Kaner RJ, et al.. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir Res. 2023, 24:6. 10.1186\/s12931-022-02292-3","journal-title":"Respir Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: Evidence-based recommendations. An official American Thoracic Society clinical practice guideline","volume":"209","author":"Raghu G","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM, et al.. Treatment of systemic sclerosis-associated interstitial lung disease: Evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2024, 209:137-52. 10.1164\/rccm.202306-1113ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(89)80608-4","article-title":"Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis","volume":"87","author":"Lomeo RM","year":"1989","unstructured":"Lomeo RM, Cornella RJ, Schabel SI, Silver RM. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med. 1989, 87:525-7. 10.1016\/s0002-9343(89)80608-4","journal-title":"Am J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu G","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al.. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018, 198:e44-68. 10.1164\/rccm.201807-1255ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: An update","volume":"58","author":"Stochmal A","year":"2020","unstructured":"Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear antibodies in systemic sclerosis: An update. Clin Rev Allergy Immunol. 2020, 58:40-51. 10.1007\/s12016-018-8718-8","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.587773","article-title":"Classical disease-specific autoantibodies in systemic sclerosis: Clinical features, gene susceptibility, and disease stratification","volume":"7","author":"Yang C","year":"2020","unstructured":"Yang C, Tang S, Zhu D, Ding Y, Qiao J. Classical disease-specific autoantibodies in systemic sclerosis: Clinical features, gene susceptibility, and disease stratification. Front Med (Lausanne). 2020, 7:587773. 10.3389\/fmed.2020.587773","journal-title":"Front Med (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0878-7","article-title":"The many faces of scleroderma sine scleroderma: A literature review focusing on cardiopulmonary complications","volume":"29","author":"Toya SP","year":"2009","unstructured":"Toya SP, Tzelepis GE. The many faces of scleroderma sine scleroderma: A literature review focusing on cardiopulmonary complications. Rheumatol Int. 2009, 29:861-8. 10.1007\/s00296-009-0878-7","journal-title":"Rheumatol Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults: An official ATS\/JRS\/ALAT clinical practice guideline","volume":"202","author":"Raghu G","year":"2020","unstructured":"Raghu G, Remy-Jardin M, Ryerson CJ, et al.. Diagnosis of hypersensitivity pneumonitis in adults: An official ATS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020, 202:e36-69. 10.1164\/rccm.202005-2032ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann ER","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet. 2023, 401:304-18. 10.1016\/S0140-6736(22)01692-0","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.009","article-title":"Independent association between occupational exposure and decline of forced vital capacity in systemic sclerosis (SSc): A multicenter recruitment retrospective cohort study","volume":"161","author":"Thoreau B","year":"2022","unstructured":"Thoreau B, Eustache M, Fievet A, Lasfargues G, Plantier L, Diot E. Independent association between occupational exposure and decline of forced vital capacity in systemic sclerosis (SSc): A multicenter recruitment retrospective cohort study. Chest. 2022, 161:1011-21. 10.1016\/j.chest.2021.11.009","journal-title":"Chest"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin DP","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016, 4:708-19. 10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland KB","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, et al.. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021, 9:96-106. 10.1016\/S2213-2600(20)30330-1","journal-title":"Lancet Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/431563-a-case-report-on-a-challenge-from-diagnosis-to-treatment-interstitial-lung-disease-as-the-first-manifestation-of-systemic-sclerosis-sine-scleroderma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:47:10Z","timestamp":1765205230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/431563-a-case-report-on-a-challenge-from-diagnosis-to-treatment-interstitial-lung-disease-as-the-first-manifestation-of-systemic-sclerosis-sine-scleroderma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.98714","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}